GET DAILY SIGNALSMacroGenics (MGNX) Analyst Targets Signal Potential +187% Upside to $7
Key Takeaways
- The central price target of $7 is the arithmetic mean of three current, named analyst price targets: $11, $6, and $4, giving a wide range of $4 to $11.
- MacroGenics, Inc. (MGNX) closed near $2.44 in late October 2026, meaning the $7 target implies a roughly 187% move — a very large gap for a clinical-stage biotech.
- Bullish targets rest on the company's antibody-drug conjugate (ADC) pipeline and its bispecific DART platform; cautious targets reflect heavy cash burn and declining revenue.
- The stock has been exceptionally volatile, including a sharp single-day decline in late October 2026 that erased a large portion of its 2026 gains.
- Analysts disagree sharply, with Stifel at $4 while B. Riley Securities is at $11 — a sign that the outcome hinges on binary clinical data rather than steady execution.
- For deeper context, explore MacroGenics' Major News, Today's Price Move, Forecast, and Earnings pages to track the factors behind the target.
- You can also follow Trending AI Robots to see how AI-driven trading strategies are positioning across the market.
Analyst Price Targets and Consensus View
Three current, attributable analyst price targets were reviewed for MacroGenics (MGNX). B. Riley Securities (Mayank Mamtani) raised its target from $9 to $11 in August 2026 while maintaining a Buy rating; Barclays (Etzer Darout) held an Overweight rating with a $6 target, raised from $4 in April 2026; and Stifel reiterated a Hold with a $4 target. The arithmetic mean of these three targets is $7.00, rounded to $7, with a range of $4 to $11.
That spread is unusually wide, reflecting fundamentally different views of the company's pipeline. More cautious analysts emphasize declining revenue, ongoing net losses, and liquidity pressure, while bullish analysts point to the ADC franchise and collaboration economics as drivers of a potential re-rating. Notably, some aggregators show a slightly higher average near $8, reflecting different analyst sets and methodologies; the $7 figure here is calculated directly from the three named targets above. TD Cowen and H.C. Wainwright also maintain Hold ratings but do not publish current price targets. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
With shares near $2.44, reaching $7 would require a gain of roughly 187% — by any measure a very large move. MacroGenics is a clinical-stage biopharmaceutical company developing antibody-based therapies for cancer, with a market capitalization of roughly $260 million. Its most recent reported quarter (August 2026) showed a wider-than-expected loss and revenue well below estimates, and consensus forecasts anticipate revenue declining materially over the next several years rather than growing.
For the stock to bridge this gap, the company would need a succession of positive catalysts — favorable clinical data, new or expanded partnerships, and a clearer path to financing that does not heavily dilute shareholders. Valuation alone does not close a gap this size for a company that is not yet profitable; the path depends primarily on pipeline outcomes.
What Could Support a Move Toward the Target
The strongest support comes from the pipeline, particularly the B7-H3-targeting ADC program MGC026 and the bispecific DART platform, which underpins candidates such as lorigerlimab (in the LORIKEET Phase 2 trial). A collaboration agreement related to ADC technology has also drawn analyst attention, and B. Riley's August upgrade to Buy signaled a more constructive view of the company's long-term monetization potential.
Biotech valuations can re-rate sharply when clinical milestones hit, and a single compelling data readout could materially shift sentiment. Insider buying and relatively high short interest (around 10.8% of float) also mean that positive news could be amplified by short covering. From what I see, the AI Pattern Search Engine on Tickeron can help flag similar setups in the sector.
What Could Prevent the Target From Being Reached
The principal obstacle is financial. MacroGenics continues to burn cash while revenue contracts, and analysts do not forecast profitability in the near term. The August 2026 earnings report — which missed on both earnings per share (EPS) and revenue — underscored execution risk, and the sharp late-October share decline suggests investors are reassessing near-term prospects.
Clinical-stage biotechs also face binary risk: a failed or disappointing trial can trigger a rapid repricing that no analyst target anticipates. Further dilution to fund research and development, competitive pressure in the crowded ADC space, and the possibility that cautious targets like Stifel's $4 prove closer to reality all weigh against the $7 mark.
Technical Levels and Market Structure
MacroGenics trades within a wide 52-week range spanning roughly $1 to $5, having climbed substantially earlier in 2026 before a sharp single-day pullback in late October. The stock has repeatedly failed to hold levels in the mid-$4s, an area that now functions as resistance. On the downside, the low-$2 zone is the most recent area of support. The wide gap between the current price and the $7 target means there are few meaningful technical barriers in between; the real determinant is fundamental news flow rather than chart structure. I’m watching this closely with help from Tickeron’s AI Trend Prediction Engine.
Time Horizon and What Investors Should Monitor
Analyst price targets for biotech companies generally reflect a 12-month research horizon, though individual firms vary, and for a company this volatile the targets are better read as scenario markers than timelines. Investors should monitor the next quarterly earnings and guidance, any updates on the MGC026 and lorigerlimab programs, partnership or licensing announcements, and cash-balance disclosures in SEC filings. Revisions from the three firms above — and any new initiations — will also signal whether the $7 mean target is moving up or down.
Using AI Daily Buy/Sell Signals for Biotech Monitoring
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. For a volatile name like MacroGenics, this kind of automated monitoring can help traders spot changing trends and manage positions more efficiently than manual tracking. Traders can use the signals to discover new opportunities, confirm their own analysis, and stay ahead of rapid sentiment shifts.
Final Assessment
The $7 central target is an analyst-derived average, not a forecast, and it sits far above the current price. It reflects a genuine split in opinion: B. Riley sees upside toward $11, while Stifel sees $4 as more realistic, with Barclays in between at $6. The gap to $7 is very large and would almost certainly require positive clinical data or a transformative partnership, because the company's current financial trajectory — falling revenue, ongoing losses, and cash burn — does not by itself support such a move. Investors should weigh the binary nature of biotech catalysts, monitor cash runway and pipeline updates, and treat the $7 figure as one scenario among several rather than an expectation.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
MGNX's Stochastic Oscillator stoops into oversold zone
The Stochastic Oscillator for MGNX moved into oversold territory on October 27, 2026. Be on the watch for the price uptrend or consolidation in the future. At that time, consider buying the stock or exploring call options.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where MGNX's RSI Indicator exited the oversold zone, 20 of 25 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
Following a +4.01% 3-day Advance, the price is estimated to grow further. Considering data from situations where MGNX advanced for three days, in 229 of 271 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
MGNX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 23, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MGNX as a result. In 79 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
The Moving Average Convergence Divergence Histogram (MACD) for MGNX turned negative on October 23, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In 47 of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
MGNX moved below its 50-day moving average on September 29, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for MGNX crossed bearishly below the 50-day moving average on September 23, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MGNX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for MGNX entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 11 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. MGNX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.625) is normal, around the industry mean (2.974). P/E Ratio (-11.091) is within average values for comparable stocks, (-0.899). Projected Growth (PEG Ratio) (10.770) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.903) among similar stocks. P/S Ratio (1.477) is also within normal values, averaging (439.237).
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MGNX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company, which engages in the discovery and development of monoclonal antibody-based therapeutics
Industry Biotechnology
Advertisement